Synchron, an endovascular brain-computer interface (BCI) company, announced a $75 million Series C financing round led by ARCH Venture Partners that was oversubscribed. ARCH welcomes new investors Gates Frontier, Bezos Expeditions, Reliance Digital Health Limited, Greenoaks, Alumni Ventures, Moore Strategic Ventures, and Project X.
The funding will be used to expedite the development of Synchron’s first platform product (Synchron SwitchTM BCI) as well as the launch of a pivotal clinical trial, said Synchron in its press release.
The Series C funding brings the total funds raised since the company’s inception to $145 million.
At around 10.05 AM, Reliance Industries was trading at Rs2,598.45 per piece, up by 0.76% from its previous closing of Rs2,578.75 on the BSE. The scrip opened at Rs2,570 and touched an intraday high and low of Rs2,619 and Rs2,570 respectively.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags

IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.